EGFR-IN-76

CAS No. 2607829-38-7

EGFR-IN-76( —— )

Catalog No. M36624 CAS No. 2607829-38-7

EGFR-IN-76 is a potent EGFR inhibitor.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 297 In Stock
10MG 471 In Stock
25MG 905 In Stock
50MG 1423 In Stock
100MG 1934 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    EGFR-IN-76
  • Note
    Research use only, not for human use.
  • Brief Description
    EGFR-IN-76 is a potent EGFR inhibitor.
  • Description
    EGFR-IN-76 (compound 37A) is a potent inhibitor of EGFR. EGFR-IN-76 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Angiogenesis
  • Target
    EGFR
  • Recptor
    EGFR
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    2607829-38-7
  • Formula Weight
    561.05
  • Molecular Formula
    C30H30ClFN6O2
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (178.24 mM; Ultrasonic )
  • SMILES
    C(#CC=1C(NC(/C=C/CN2CCOCC2)=O)=CC3=C(C1)N=CN=C3NC4=C(F)C(Cl)=CC=C4)[C@]56[C@](C5)(CN(C)C6)[H]
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Lucas MC, et al. Preparation of alkynyl quinazoline compounds as anticancer agents. World Intellectual Property Organization, WO2021030711 A1. 2021-02-18.
molnova catalog
related products
  • AG-1517

    PD153035 hydrochloride is a potent and specific inhibitor of EGFR with Ki and IC50 of 5.2 pM and 29 pM in cell-free assays; little effect noted against PGDFR, FGFR, CSF-1, InsR and Src.

  • Theliatinib

    Theliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.

  • HKI-357

    HKI-357 is an irreversible dual inhibitor of EGFR and ERBB2 (IC50s: 34 nM and 33 nM). HKI-357 suppresses EGFR autophosphorylation (at Y1068), and AKT and MAPK phosphorylation.